Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Fortrea completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million. The deal adds a 200-bed GCP-compliant clinical research unit in San Antonio, a 60,000-square-foot GLP-compliant bioanalytical lab in Austin, and a biospecimen storage facility in Pflugerville, expanding Fortrea's early-phase capacity to more than 570 beds globally. Management framed the closing as tangible progress in Fortrea's return to growth, adding in-house large and small molecule bioanalytical capabilities and reducing operational handoffs for early-phase studies.
Key figures
- Deal Value Usd
- 45000000
- Early phase beds
- more than 570 globally
- Acquired cru beds
- 200
- Acquired lab size
- 60,000 square feet
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.